The presence of antibodies reacting with soluble extractable nuclear antigens (ENA) in the serum of patients with systemic lupus erythematosus (SLE) was established for the first time by Holman et al. (1959) .
Subsequent studies led to the identification of two of these antigens (antigens Sm and RNP) (Tan and Kunkel, 1966; Mattioli and Reichlin, 1971 ) and more recently of 3 or 4 other antigens (PM1, SSA and SSB, and antigen Ha; Alspaugh and Tan, 1973; Akizuki et al., 1977; Wolfe et al., 1977) . One of us (Peltier et al., 1977b) has recently characterised a soluble nuclear antigen which seems to be a protein and whose properties are very similar to those of antigen Ha and antigen SSB.
Accepted for publication November 13, 1977 Correspondence to Dr A. P. Peltier The interest in these antigens was stimulated by the description of Sharp and his co-workers (1972) of the entity they called 'mixed connective tissue disease', in which the anti-RNP antibodies are the immunological markers the most characteristic of the disease. Since the initial description by Sharp et al., many studies have attempted to define further the clinical significance of antibodies to different soluble nuclear antigens and particularly antibodies to RNP (Koffler et al., 1971; Griffiths et al., 1977) . The data obtained have not always been similar. We report here our own studies with 176 sera which contained antibodies to soluble antigens.
Material and methods
The detection of antinuclear antibodies (ANA) was done by indirect immunofluorescence on 4 ,tm cryostat cut sections of normal young rat liver, using various dilutions of the patient's serum starting at a 1:10 dilution and a commercially obtained polyvalent anti-human immunoglobulins rabbit antiserum labelled with fluorescein isothiocyanate (Institut Pasteur, Paris).
Study of the antibodies to ENA was done on all sera containing ANA which exhibited a speckled pattern of nuclear fluorescence or, at the request of the physician, when mixed connective tissue disease was suspected. This was done using precipitation in Agar gel by the technique of Ouchterlony. The preparation of the thymic cells extract and its treatment by RNase or trypsin have been previously described (Peltier et al., 1977a ). Each serum was tested against native ENA, ENA treated with RNase, and ENA treated with trypsin. The reactions were read after 3 or 4 days incubation of the plates at 4°C in a humid chamber. The sera reacting with the 3 forms of the extract were considered to contain anti-Sm, those reacting only with native ENA to contain anti-RNP, and those reacting with native and RNase-treated ENA (but not with trypsin-treated ENA), to contain antibodies to the soluble nuclear protein antigen. Antibodies to this latter antigen will be described here as 'anti-protein'. The exact specificity of the precipitin lines observed was initially controlled by demonstrating their identity by comparison with precipitin lines of anti-Sm and anti-RNP sera (supplied by E. Tan). Some sera gave more than one precipitin line and were therefore considered as containing multiple antibodies to ENA. An association of anti-Sm and anti-RNP antibodies was most commonly found.
Detection of anti-DNA antibodies was performed using either an indirect immunofluorescent spot test on DNA spread on slides (Osnos et al., 1977) , by the radio-immunoassay technique of Farr (Peltier et al., 1974) , or by both techniques.
Results

GENERAL RESULTS
The sera of 1169 patients were studied. One hundred and seventy-six of these sera gave a positive reaction to ENA on one or more occasions. The majority of the positive sera (64%) contained an anti-RNP antibody and a small proportion had either antiSm, anti-protein, or multiple antibodies (Table 1) .
We had access to the charts of 134 of these 176 patients. Only the clinical data of these 134 patients were used in this study. Fig. 1 , the distribution of the titres of ANA is apparently different for the sera containing anti-Sm or anti-protein antibodies than for the anti-RNP containing sera. The latter have a serum ANA concentration a little more elevated than the former.
SEROLOGICAL AND CLINICAL CORRELATIONS
The major clinical manifestations of the patients with anti-ENA are shown in Table 3 . The female predominance, the age of onset of symptoms, and the duration of disease since the first symptom are similar for all categories of patients.
The clinical manifestations found most frequently among all the groups were arthritis (85 to 100%) and Raynaud's phenomenon (50 to 76%). Fever was present in all groups (40 to 73%). Swollen fingers were common in patients with anti-RNP (34 %). Other manifestations were observed in less than one third of the patients. Sj6gren's disease was common in patients having anti-soluble nuclear protein (30 %). anti-Sm; *-A: anti-RNP; -v: multiple antibodies. The arthritis was generally benign although 16 patients (10 with anti-RNP) had erosive arthritis and 16 (7 with anti-RNP) had deformities. Seven patients (3 with anti-RNP) had rheumatoid nodules.
It must be noted that Raynaud's phenomenon was often the first sign of the disease existing on its own for many years. In certain patients the swollen fingers evolved into definite sclerodactyly.
Abnormalities of the muscles were considered to be present only in patients having, in addition to the clinical symptoms of myalgia (28 of 134 patients) and muscle weakness or atrophy, one or more biological signs suggestive of myositis (elevation of muscles enzymes, abnormal electromyogram, muscle biopsy showing myositis). None of the 20 patients who fitted this category had the heliotrope rash characteristic of dermatomyositis.
Neuropsychiatric manifestations were very heterogeneous. Of the patients with anti-RNP, 2 had seizures disorders of long duration before the onset of their illness, 1 had a history of a facial palsy, and 1 had a serious meningitis during the course of connective tissue disease. Of the patients with anti-Sm 1 had had myasthenia 20 years before the diagnosis of SLE. One of the patients with anti-protein developed a Brown-Sequard syndrome and another had major psychiatric problems. Of the 3 patients with multiple antibodies 2 had psychosis and 1 a pyramidal syndrome.
RENAL MANIFESTATIONS
A 24-hour urine protein test was done in 106 of the 134 patients with anti-ENA, serum creatinine tests were performed in 110, and 38 patients had a renal biopsy.
Definite renal disease was considered to be present if 24-hour urine was more than 1 g (5 95 mmol), serum creatinine more than 1-5 mg/100 ml (13-26 limol/l), or if a renal biopsy showed histological abnormalities typical of glomerulonephritis.
Possible renal disease was considered to be present if there was a proteinuria between 250 mg and 1 g/24 hour and/or minimal glomerular alterations.
Using these criteria (see Table 3 ), definite renal disease was found more frequently in patients with anti-Sm or multiple antibodies than in patients with anti-RNP or anti-protein, while possible renal disease was found more frequently in patients with anti-protein or multiple antibodies than in patients with anti-Sm or anti-RNP. Taking the 2 subgroups together seems to show that renal disease is more frequent in patients with anti-protein (40 %), anti-Sm (39%) or multiple antibodies (63 %), than in those with anti-RNP (25 %). Table 4 shows the incidence of anti-DNA in 37 patients with anti-ENA who had renal biopsies. It is of interest that a majority (13 out of 15) of the patients with histologically significant renal disease (extramembranous, diffuse proliferative, or local proliferative glomerulonephritis) had anti-DNA in addition to anti-ENA. A similar proportion (6 out of 7) is found in the group of patients with anti-RNP.
Two patients had renal disease without anti-DNA. The first, with anti-RNP who had extramembranous glomerulonephritis developed nephrotic syndrome after receiving penicillamine; the second, with anti-Sm, had local proliferative glomerulonephritis. LABORATORY 
DATA
As we are dealing with a retrospective study, the laboratory data could not be collected uniformly for all the 134 patients. Therefore, the results in Table 5 Sharp et al. (1976) using bbth techniques comparatively, found discrepancies in favour of haemagglutination in 2 of 67 sera with anti-RNP and in 6 of 27 sera having antibodies specific for an RNase resistant antigen.
In this study, the majority of sera with anti-RNP gave a speckled pattern of nuclear fluorescence. The percentages observed are lower for sera with anti-Sm, anti-protein, and multiple antibodies. This difference can probably be explained by the more frequent presence in these sera of anti-DNA, anti-DNA protein, and other antibodies (Tan, 1967) .
The finding, in sera with anti-RNP, of titres of ANA higher than in sera with anti-Sm, has already been observed (Sharp et al., 1976) .
Most important in fact, is the discussion of the clinical significance of anti-RNP antibodies. Two major questions arise here: is the presence of anti-RNP in the serum of patient, characteristic of the entity described by Sharp et al. (1972) (Tuffanelli and Winkelmann, 1961; Dubois et al., 1971) , and 28% a limited clinical syndrome consisting of Raynaud's phenomenon and a more or less isolated polyarthritis.
In fact, our results are in agreement with previously published series where no diagnostic specificity was found for anti-RNP antibody (Mattioli and Reichlin, 1971; Parker, 1973; Notman et al., 1975) .
Two explanations have been proposed for the good prognosis and the low incidence of nephritis in patients with anti-RNP antibodies. Mattioli and Reichlin (1971) found a very low incidence of anti-DNA antibodies in their patients with anti-RNP antibodies. One experimental study showed a protective effect of ENA on the development ofnephritis in NZB/NZW mice (Morris et al., 1975) .
We should mention here that two patients with anti-RNP and anti-DNA antibodies died during the course of our study. They were both cases of SLE. The first died of renal failure and the second of acute respiratory failure.
Our results indicate a narrower specificity of anti-Sm and anti-protein for SLE, since this diagnosis was made in more than half the patients with these antibodies. These figures never reach the specificity claimed by Tan and Kunkel (1966) for anti-Sm antibodies.
Finally, it must be concluded that the antibodies to ENA, in particular anti-RNP and anti-Sm, although they are of great interest in our knowledge of this group of diseases, are far from reaching, for the physician, the diagnostic and prognostic values of other antibodies mainly anti-DNA.
